Zacks: CRISPR THERAPTC (CRSP) Given Average Rating of “Strong Buy” by Analysts – BBNS
|
Zacks: CRISPR THERAPTC (CRSP) Given Average Rating of "Strong Buy" by Analysts
BBNS CRISPR THERAPTC logo Shares of CRISPR THERAPTC (NASDAQ:CRSP) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts … |
